Recovery & TissueKLOW
80 mg · Lyophilized Powder
Four-component blend for broad laboratory signalling research.
Batch COA available by email on request
Published areas of interest.
This page summarises published research areas for general information. It does not establish safety, efficacy, or suitability for any use.
KLOW combines KPV, BPC-157, TB-500 and GHK-Cu. No peer-reviewed publication was identified for this exact four-component blend; published research examines the components separately.
Areas of research interest
Current evidence
The evidence is component-specific, not blend-specific. Separate studies use different molecules, formulations, routes and endpoints. Those findings cannot be added together to predict a combined effect.
Important limitations
The exact blend lacks direct published evidence. Potential interactions, stability, product quality, safety and longer-term outcomes have not been established through direct clinical studies of KLOW.
Documentation for this material.
Janoshik Certificate of Analysis available by email. Contact us with the product name and batch number.
Understand our testingFor research use only.
Not for human or animal consumption. Not an approved therapeutic good. The TGA identifies KLOW as an unapproved therapeutic good in Australia.